Middleton Lavinia P, Amin Mitual, Gwyn Karin, Theriault Richard, Sahin Aysegul
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, PO Box 85, Houston, TX 77030, USA.
Cancer. 2003 Sep 1;98(5):1055-60. doi: 10.1002/cncr.11614.
Breast carcinoma is one of the most common carcinomas in pregnant women. The incidence of breast carcinoma may increase in the future because of the trend toward delayed childbearing and increased screening. However, very few contemporary studies have attempted to identify the combined histopathologic and immunohistochemical features of breast carcinoma in these patients.
The authors evaluated 39 patients with breast carcinoma occurring coincident with pregnancy. This was comprised of a critical histologic review and immunohistochemical evaluation to determine the status of prognostic and predictive markers including estrogen receptor (ER), progesterone receptor (PR), HER-2/neu, Ki-67, and p53.
The mean age at presentation was 33 years (range, 24-44 years). Densities and/or masses were noted on mammograms in 14 of 16 patients with available radiographic information. The primary tumors were a mean of 4.5 cm in greatest dimension (range, 0.1-13.5 cm). Two of the 39 patients had clinical (American Joint Committee on Cancer) Stage I disease, 19 patients had Stage II disease, 16 had Stage III disease, and 2 patients had Stage IV disease at the time of presentation. Histologically, high-grade invasive ductal carcinomas were found in 32 of 38 patients. The primary tumor was not available for review in one patient. A predominantly solid pattern of growth was observed in nine patients. Lymphovascular invasion was identified in 61% of cases. Ductal carcinoma in situ was identified in 72% of tumors and was high grade in all cases. Of the 25 patients tested, ER positivity was found in 7 patients, PR positivity was found in 6 patients, HER-2/neu positivity was found in 7 patients, and p53 positivity was found in 12 patients. The proliferation rate as shown by Ki-67 staining was high in 60% of the cases. Follow-up information was available for 35 patients and the mean follow-up period was 43 months (range, 2-163 months). Distant metastasis occurred in seven patients. The mean time to disease recurrence was 20.4 months (range, 10-33 months). Of 35 patients, 4 have died, 22 were alive with no evidence of disease, and 9 were alive with disease at the last follow-up. The remaining four patients died of unknown causes.
Pregnant women with breast carcinomas generally present with advanced-stage disease and the tumors have poor histologic and prognostic features. The findings from the follow-up indicated that these tumors do not follow a very aggressive clinical course as was proposed in earlier reports. Breast carcinomas occurring during pregnancy share many histologic and prognostic similarities with breast carcinoma occurring in other young women.
乳腺癌是孕妇中最常见的癌症之一。由于生育推迟和筛查增加的趋势,未来乳腺癌的发病率可能会上升。然而,很少有当代研究试图确定这些患者乳腺癌的组织病理学和免疫组化联合特征。
作者评估了39例妊娠合并乳腺癌患者。这包括严格的组织学检查和免疫组化评估,以确定预后和预测标志物的状态,包括雌激素受体(ER)、孕激素受体(PR)、HER-2/neu、Ki-67和p53。
就诊时的平均年龄为33岁(范围24 - 44岁)。在16例有可用影像学信息的患者中,14例乳房X线照片上发现密度和/或肿块。原发肿瘤最大直径平均为4.5 cm(范围0.1 - 13.5 cm)。39例患者中有2例临床(美国癌症联合委员会)分期为I期疾病,19例为II期疾病,16例为III期疾病,2例就诊时为IV期疾病。组织学上,38例患者中有32例为高级别浸润性导管癌。1例患者的原发肿瘤无法进行复查。9例患者观察到主要为实性生长模式。61%的病例发现有淋巴管浸润。72%的肿瘤中发现导管原位癌,且所有病例均为高级别。在25例接受检测的患者中,7例ER阳性,6例PR阳性,7例HER-2/neu阳性,12例p53阳性。Ki-67染色显示的增殖率在60%的病例中较高。35例患者有随访信息,平均随访期为43个月(范围2 - 163个月)。7例患者发生远处转移。疾病复发的平均时间为20.4个月(范围10 - 33个月)。在35例患者中,4例死亡,22例存活且无疾病证据,9例在最后一次随访时存活但有疾病。其余4例患者死因不明。
妊娠合并乳腺癌的孕妇通常表现为晚期疾病,肿瘤具有不良的组织学和预后特征。随访结果表明,这些肿瘤并不像早期报告中所提出的那样具有非常侵袭性的临床病程。妊娠期间发生的乳腺癌与其他年轻女性发生的乳腺癌在许多组织学和预后方面具有相似性。